Exposure–response relationship of olaratumab for survival outcomes and safety when combined with doxorubicin in patients with soft tissue sarcoma

被引：0
|
作者：
Robin L. Jones
Gary Mo
John R. Baldwin
Patrick M. Peterson
Robert L. Ilaria
Ilaria Conti
Damien M. Cronier
William D. Tap
机构：
[1] University of Washington and Fred Hutchinson Cancer Research Center,
[2] Eli Lilly and Company,undefined
[3] Lilly Corporate Center,undefined
[4] Eli Lilly and Company,undefined
[5] Lilly Research Centre,undefined
[6] Memorial Sloan Kettering Cancer Center and Weill Cornell Medical College,undefined
[7] Royal Marsden Hospital and Institute of Cancer Research,undefined
[8] Celgene,undefined
[9] EMD Serono Research & Development Institute,undefined
[10] Merck Serono Ltd,undefined
来源：
Cancer Chemotherapy and Pharmacology | 2019年 / 83卷
关键词：
Olaratumab; Doxorubicin; Exposure response; Outcome; Soft tissue sarcomas;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
页码：191 / 199
页数：8
相关论文
共 50 条
  • [1] Exposure-response relationship of olaratumab for survival outcomes and safety when combined with doxorubicin in patients with soft tissue sarcoma
    Jones, Robin L.
    Mo, Gary
    Baldwin, John R.
    Peterson, Patrick M.
    Ilaria, Robert L., Jr.
    Conti, Ilaria
    Cronier, Damien M.
    Tap, William D.
    CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2019, 83 (01) : 191 - 199
  • [2] Exposure-response of olaratumab for survival outcomes and safety when combined with doxorubicin in soft tissue sarcoma (STS) patients
    Jones, R.
    Mo, G.
    Baldwin, J. R.
    Nichols, R. D.
    Ilaria, R. L.
    Conti, I.
    Cronier, D. M.
    Tap, W. D.
    ANNALS OF ONCOLOGY, 2016, 27
  • [3] Olaratumab combined with doxorubicin and ifosfamide overcomes individual doxorubicin and olaratumab resistance of an undifferentiated soft-tissue sarcoma in a PDOX mouse model
    Higuchi, Takashi
    Miyake, Kentaro
    Sugisawa, Norihiko
    Oshiro, Hiromichi
    Zhang, Zhiying
    Razmjooei, Sahar
    Yamamoto, Norio
    Hayashi, Katsuhiro
    Kimura, Hiroaki
    Miwa, Shinji
    Igarashi, Kentaro
    Bouvet, Michael
    Singh, Shree Ram
    Tsuchiya, Hiroyuki
    Hoffman, Robert M.
    CANCER LETTERS, 2019, 451 : 122 - 127
  • [4] A Phase Ib study assessing biomarker modulation in soft tissue sarcoma patients treated with olaratumab followed by olaratumab plus doxorubicin
    Martin-Broto, Javier
    Lopez Pousa, Antonio
    Brohl, Andrew
    Van Tine, Brian A.
    Powers, Benjamin
    Stacchiotti, Silvia
    Blay, Jean-Yves
    Hu, James S.
    Oakley, Gerard J.
    Wang, Hong
    Szpurka, Anna
    Levy, Donna E.
    Mo, Gary
    Ceccarelli, Matteo
    Jones, Robin
    CANCER RESEARCH, 2019, 79 (13)
  • [5] Olaratumab and doxorubicin for the treatment of metastatic soft tissue sarcoma: a retrospective case series
    Hur, Joon Young
    Park, Se Hoon
    Lee, Su Jin
    PRECISION AND FUTURE MEDICINE, 2019, 3 (02): : 77 - 84
  • [6] A pilot study of first-line olaratumab, doxorubicin and ifosfamide in patients with metastatic soft tissue sarcoma
    Olga Vornicova
    Nissim Haim
    Gil Bar-Sela
    Cancer Chemotherapy and Pharmacology, 2019, 84 : 919 - 923
  • [7] Phase 1 study of olaratumab plus doxorubicin in Japanese patients with advanced soft-tissue sarcoma
    Yonemori, Kan
    Kodaira, Makoto
    Satoh, Taroh
    Kudo, Toshihiro
    Takahashi, Shunji
    Nakano, Kenji
    Ando, Yuichi
    Shimokata, Tomoya
    Mori, Joji
    Inoue, Koichi
    Oakley, Gerard J.
    Sakaguchi, Sachi
    Tamura, Kenji
    CANCER SCIENCE, 2018, 109 (12) : 3962 - 3970
  • [8] A pilot study of first-line olaratumab, doxorubicin and ifosfamide in patients with metastatic soft tissue sarcoma
    Vornicova, Olga
    Haim, Nissim
    Bar-Sela, Gil
    CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2019, 84 (04) : 919 - 923
  • [9] ASCO 2017 Soft Tissue Sarcoma - Olaratumab extends the Survival by almost a Year
    不详
    ONCOLOGY RESEARCH AND TREATMENT, 2017, 40 (12)
  • [10] Circulating Tumor Cells and Biomarker Modulation with Olaratumab Monotherapy Followed by Olaratumab plus Doxorubicin: Phase Ib Study in Patients with Soft-Tissue Sarcoma
    Martin-Broto, Javier
    Pousa, Antonio Lopez
    Brohl, Andrew S.
    Van Tine, Brian A.
    Powers, Benjamin
    Stacchiotti, Silvia
    Blay, Jean-Yves
    Hu, James S.
    Oakley, Gerard J.
    Wang, Hong
    Szpurka, Anna M.
    Levy, Donna E.
    Mo, Gary
    Ceccarelli, Matteo
    Jones, Robin L.
    MOLECULAR CANCER THERAPEUTICS, 2021, 20 (01) : 132 - 141
12345